Table 2.
Clinical Variables Stratified According to “True” Or “False” Clinical Stage III-ssN2
| Clinical variable | Cohort A (GM) (n = 56) |
Cohort B (UK) (n = 59) |
Combined study cohort (N = 115) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| True: ssN2 (n = 37) | False: msN2 (n = 19) | p-Value | True: ssN2 (n = 40) | False: msN2 (n = 19) | p-Value | True: ssN2 (n = 77) | False: msN2 (n = 38) | p-Value | ||
| Tumor size (mm) | Median (IQR) | 29 (22–36) | 32 (20–44) | 0.33 | 35 (23–46) | 36 (30–60) | 0.39 | 32 (26–43) | 34 (24–52) | 0.44 |
| Tumor SUVmax | Median (IQR) | 10 (8.1–14) | 12 (9.3–14.7) | 0.25 | 9.9 (8–13.4) | 13.3 (8.4–15.1) | 0.29 | 9.9 (8–13.6) | 12.8 (8.8–14.9) | 0.21 |
| Tumor location (side) | Right n (%) | 32 (87) | 12 (63) | 24 (60) | 11 (58) | 0.88 | 56 (73) | 23 (61) | ||
| Left n (%) | 5 (13) | 7 (37) | 0.08 | 16 (40) | 8 (42) | 21 (27) | 15 (39) | 0.18 | ||
| Tumor location (lobe) | RUL | 19 (51) | 5 (26) | 6 (15) | 8 (42) | 25 (33) | 13 (34) | |||
| RML/RLL | 13 (35) | 7 (37) | 18 (45) | 3 (16) | 31 (40) | 10 (26) | ||||
| LUL | 1 (3) | 4 (21) | 12 (30) | 6 (32) | 0.12 | 13 (17) | 10 (26) | |||
| LLL | 4 (11) | 2 (11) | 4 (10) | 2 (11) | 8 (10) | 4 (11) | ||||
| LMB | 0 (0) | 1 (5) | 0.08 | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0.47 | ||
| Tumor sub-type | Adenocarcinoma/NOS | 23 (62) | 6 (32) | 28 (70) | 12 (63) | 51 (66%) | 18 (47) | |||
| Squamous cell carcinoma | 14 (38) | 13 (68) | 0.05 | 12 (30) | 7 (37) | 0.60 | 26 (34) | 20 (53) | 0.052 | |
GM, Greater Manchester; IQR, interquartile range; LLL, left lower lobe; LMB, left main bronchus; LUL, left upper lobe; msN2, multi-station N2; NOS, not otherwise specified; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; ssN2, single-station N2; SUVmax, maximum standardized uptake value.